Scholarlink

<p>The optimal therapeutic approach for primary mediastinal B-cell lymphoma remains unknown and varies in clinical practice. Dose-adjusted EPOCH-R or R-CHOP-based immuno-chemotherapy with mediastinal radiotherapy are acceptable treatment options. We report a retrospective analysis of PMBL patients treated with high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) consolidation or dose-dense immuno-chemotherapy alone. A comparison of the two consolidation strategies showed no significant difference in 5-year PFS (95.5% vs. 82.4%, HR 0.22 95% CI 0.03–1.69, <i>p</i> = 0.13) or OS (100% vs. 87.1%, HR 0.1 95% CI 0.006–1.69, <i>p</i> = 0.11), with a trend toward better survival in the preplanned HDCT/ASCT group. Notably, 35.3% of patients received additional HDCT/ASCT after an inadequate response to dose-dense immuno-chemotherapy. When comparing all patients, with or without first-line HDCT/ASCT consolidation, regardless of the initial consolidation strategy, we found a significant difference in 5-year PFS (96.2% vs. 75%, HR 0.09 95% CI 0.01–0.83, <i>p</i> = 0.03) and OS (100% vs. 80.1%, HR 0.03 95% CI 0.002–0.7, <i>p</i> = 0.03) for patients treated with HDCT/ASCT. In addition, mediastinal radiotherapy was administered significantly less frequently in patients treated with HDCT/ASCT. In conclusion, high-dose chemotherapy and autologous stem cell transplantation may be a valid strategy to induce a favorable long-term outcome and spare radiotherapy in patients with PMBL.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Primary mediastinal B-cell lymphoma: upfront high-dose chemotherapy with autologous stem cell transplantation results in favorable long-term outcome and may spare radiotherapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月17日

查看全文
  • Tino Vollmer,
  • Tim Strüßmann,
  • Franziska Glatzki,
  • Konrad Aumann,
  • Kristina Fritsch,
  • Justus Duyster,
  • Roland Mertelsmann,
  • Jürgen Finke,
  • Reinhard Marks

摘要

The optimal therapeutic approach for primary mediastinal B-cell lymphoma remains unknown and varies in clinical practice. Dose-adjusted EPOCH-R or R-CHOP-based immuno-chemotherapy with mediastinal radiotherapy are acceptable treatment options. We report a retrospective analysis of PMBL patients treated with high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) consolidation or dose-dense immuno-chemotherapy alone. A comparison of the two consolidation strategies showed no significant difference in 5-year PFS (95.5% vs. 82.4%, HR 0.22 95% CI 0.03–1.69, p = 0.13) or OS (100% vs. 87.1%, HR 0.1 95% CI 0.006–1.69, p = 0.11), with a trend toward better survival in the preplanned HDCT/ASCT group. Notably, 35.3% of patients received additional HDCT/ASCT after an inadequate response to dose-dense immuno-chemotherapy. When comparing all patients, with or without first-line HDCT/ASCT consolidation, regardless of the initial consolidation strategy, we found a significant difference in 5-year PFS (96.2% vs. 75%, HR 0.09 95% CI 0.01–0.83, p = 0.03) and OS (100% vs. 80.1%, HR 0.03 95% CI 0.002–0.7, p = 0.03) for patients treated with HDCT/ASCT. In addition, mediastinal radiotherapy was administered significantly less frequently in patients treated with HDCT/ASCT. In conclusion, high-dose chemotherapy and autologous stem cell transplantation may be a valid strategy to induce a favorable long-term outcome and spare radiotherapy in patients with PMBL.